N-hexadecyl(1,3,5-triaza-7-phosphaadamantane) hexafluorophosphate | 1397284-22-8

• 英文名称: N-hexadecyl(1,3,5-triaza-7-phosphaadamantane) hexafluorophosphate
• 英文别名: hexadecyl-(1,3,5-triaza-7-phosphaadamantane)hexafluorophosphate；hexadecyl-PTA hexafluorophosphate
• CAS: 1397284-22-8
• 化学式: C₂₂H₄₅N₃P*F₆P
• 分子量: 527.557
• InChiKey: GTCQGIYGFPQHSL-AYEGBANISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  None
• 重原子数：
  None
• 可旋转键数：
  None
• 环数：
  None
• sp3杂化的碳原子比例：
  None
• 拓扑面积：
  None
• 氢给体数：
  None
• 氢受体数：
  None

反应信息

• 作为反应物：
  描述：

  dichloro( 1,5-cyclooctadiene)platinum(ll) 、 N-hexadecyl(1,3,5-triaza-7-phosphaadamantane) hexafluorophosphate 以 二氯甲烷 为溶剂， 以83.5%的产率得到[PtCl2(hexadecyl-PTA)2][PF6]2
  参考文献：
  名称：

  PTA新长尾衍生物（1,3,5-triaza-7-phosphaadamantane）的铂和钌配合物：对人肿瘤细胞系的合成，表征和抗增殖活性

  摘要：

  PTA（1,3,5-triaza-7-phosphaadamantane）与长链烷基碘化物的烷基化反应产生了新型离子衍生物（PTAC 12 H 25）I，（PTAC 16 H 33）I和（PTAC 18 H 37）一世。阴离子交换，得到PF 6 -类似物（PTAC 12 ħ 25）PF 6，（PTAC 16 ħ 33）PF 6和（PTAC 18 ħ 37）PF 6。通过ESI-MS，元素分析，1 H，13 C和31表征了新的膦研究了P NMR谱及其对Pt（II）和Ru（II）核的配位能力。络合物顺- [氯铂酸2（PTAR）]（PF 6）2（1 - 3）和[CpRuCl（PPH 3）（PTAR）] I（5 - 7）已被分离和表征。与顺铂相比，针对每种复合物与合适的人类肿瘤细胞系（T2，SKOV3和SW480）的抗增殖活性，以估计的IC 50进行了测试，并带有母体复合物[CpRuCl（PPh

  DOI：

  10.1016/j.ica.2012.04.031

文献信息

• Lipid-based nanoparticles containing cationic derivatives of PTA (1,3,5-triaza-7-phosphaadamantane) as innovative vehicle for Pt complexes: Production, characterization and in vitro studies
  作者：Rita Cortesi、Chiara Damiani、Laura Ravani、Lorenza Marvelli、Elisabetta Esposito、Markus Drechsler、Antonella Pagnoni、Paolo Mariani、Fabio Sforza、Paola Bergamini

  DOI：10.1016/j.ijpharm.2015.07.021

  日期：2015.8

  The aliphatic phosphine PTA (1,3,5-triaza-7-phosphaadamantane) is a promising ligand for metal complexes designed and developed as innovative inorganic drugs.In the present paper, an N-alkylated derivative of PTA, (PTAC(16)H(33))X (X = I, Cl, or X = PF6, C2) and its platinum coordination complex cis-[PtCl2(PTAC(16)H(33))(2)](PF6)(2), C3, were considered as components of cationic lipid nanoparticles (CLNs). Particularly, CLN1, CLN2 and CLN3 were obtained by adding derivatives C1, C2 or C3 during nanoparticles preparation, while CLN2-Pt were obtained by treating preformed CLN2 with Pt(II). It was demonstrated that CLN1, CLN2 and CLN3 can be produced with technological conventional methods. However, among the two here proposed protocols, the one based on the treatment of preformed nanoparticles appears more advantageous as compared to the other since it allows a quantitative association yield of Pt. As determined by ICP-OES, a content of P and Pt 2.2-fold and 2.5-fold higher in CLN2-Pt than in CLN3 was evidenced. For the first time was demonstrated that properly functionalized preformed nanoparticles can be efficiently used to obtain a post production Pt(II) complex while maintaining a cytotoxic activity toward cultured cells. In fact, the antiproliferative activity shown by CLN3, CLN2-Pt on the three model cancer cell lines was substantially similar and comparable to that of complex C3 in dmso solution. Thus N-alkylated-PTA derivatives in CLNs could be proposed as innovative biocompatible and water dispersible nanoparticles carrying lipophilic Pt complexes becoming an interesting and improved system with respect to dmso solution. (C) 2015 Elsevier B.V. All rights reserved.